Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
A newer licensed oral option has recently joined these treatments
The research findings highlight the absence of a connection between clinical benefits and short-term cost savings, with the study authors concluding: "Our 24-month analysis did not demonstrate cost savings, in contrast to industry-sponsored models that project long-term savings (eg, over 10 years) based on trial-derived effectiveness. There have been fewer studies focused on the more recently approved tirzepatide-based drug Zepbound
This difference raises concerns about safety and efficacy, making it vital for patients to approach compounded options with caution
It's important to note that while Wegovy and Zepbound are FDA-approved for chronic weight management, similar medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes and may be used off-label for weight loss
